Back

Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses

Gallon, S.; Baffour Tonto, P.; Ding, Y.; Chen, G.-H.; Naito-Keoho, K.; Brites, C.; Netto, E. M.; Wang, W.-K.; Herrera, B. B.

2026-06-01 infectious diseases
10.64898/2026.05.22.26353817 medRxiv
Show abstract

Antibody-dependent enhancement (ADE) is a major concern across orthoflavivirus infections, yet how multiple viral exposures shape enhancement risk remains incompletely understood. Here, we integrated serosurveillance from Saude, Brazil with functional immunologic analyses to define how yellow fever virus (YFV)-associated orthoflavivirus immune histories influence ADE phenotypes. Using serocomplex-specific anti-premembrane antibody profiling validated by microneutralization assays, plasma samples were stratified into YFV-only, YFV+DENV, and YFV+DENV+ZIKV exposure groups. In Fc gamma receptor-bearing U937 cells, YFV-only plasma demonstrated minimal enhancement activity, whereas cumulative orthoflavivirus exposure generated broader ADE phenotypes across heterologous viruses. In IFNAR1-/- passive-transfer models, YFV-only plasma did not enhance ZIKV or DENV2 infection in vivo. In contrast, YFV+DENV plasma increased ZIKV viremia and accelerated mortality kinetics, while YFV+DENV+ZIKV plasma demonstrated concentration-dependent enhancement phenotypes. Collectively, these findings indicate that isolated YFV immunity does not predispose to ADE, whereas cumulative orthoflavivirus exposure generates antibody repertoires capable of producing concentration-dependent enhancement in vivo.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 6%
18.6%
2
Cell Reports
1338 papers in training set
Top 4%
8.4%
3
JCI Insight
241 papers in training set
Top 0.3%
8.4%
4
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 11%
6.3%
5
PLOS Pathogens
721 papers in training set
Top 3%
4.8%
6
eLife
5422 papers in training set
Top 20%
4.3%
50% of probability mass above
7
Frontiers in Immunology
586 papers in training set
Top 2%
3.9%
8
mBio
750 papers in training set
Top 4%
3.9%
9
Science Translational Medicine
111 papers in training set
Top 0.9%
3.6%
10
iScience
1063 papers in training set
Top 9%
2.3%
11
Viruses
318 papers in training set
Top 2%
2.1%
12
PLOS Biology
408 papers in training set
Top 7%
2.1%
13
Science Advances
1098 papers in training set
Top 15%
1.9%
14
Cell Host & Microbe
113 papers in training set
Top 3%
1.9%
15
Immunity
58 papers in training set
Top 2%
1.8%
16
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.7%
17
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
18
Nature Microbiology
133 papers in training set
Top 3%
1.3%
19
Cell
370 papers in training set
Top 13%
1.3%
20
The Lancet Microbe
43 papers in training set
Top 0.8%
1.2%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.1%
22
Science
429 papers in training set
Top 18%
0.9%
23
Virus Evolution
140 papers in training set
Top 1%
0.9%
24
eBioMedicine
130 papers in training set
Top 3%
0.9%
25
EMBO Molecular Medicine
85 papers in training set
Top 3%
0.9%
26
Science Immunology
81 papers in training set
Top 2%
0.8%
27
Clinical & Translational Immunology
22 papers in training set
Top 0.3%
0.7%
28
The Journal of Immunology
146 papers in training set
Top 2%
0.7%
29
Journal of Virology
456 papers in training set
Top 3%
0.7%
30
The Journal of Infectious Diseases
182 papers in training set
Top 5%
0.7%